Login to Your Account

Infinity Winnows Pipeline After Phase II Retaspimycin Miss

By Staff Reports

Wednesday, September 25, 2013
Focus at Infinity Pharmaceuticals Inc., which had shifted in the wake of disappointing data from its Hedgehog inhibitor program in early 2012, narrowed further this week following a Phase II miss with heat-shock protein 90 (Hsp90) inhibitor retaspimycin hydrochloride in non-small-cell lung cancer (NSCLC).

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription